Adgyl Lifesciences Private Limited offers a wide range of Drug Discovery Services and Development Services, including but not limited to, Medicinal Chemistry, in vitro Biology, in vivo Pharmacology, in vitro ADME, Safety Assessment, CMC and CDMO, primarily to Pharmaceutical and Biotech companies with small molecules and biologics in their pipeline, at various stages of drug development. The services offered may be exploratory in nature, under non-GLP, or regulatory in nature, under GLP compliance. Adgyl Lifesciences also offers non-GMP and cGMP synthesis services for early and late clinical development.
Adgyl Lifesciences is the first GLP-accredited laboratory in India and has been successfully audited by the USFDA (2012 and 2016) for GLP studies submitted as part of IND / NDA packages.
Its vivarium was the first to have been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) since 2001 and all animal study protocols are reviewed and approved by the Institutional Animal Ethics Committee (IAEC), which is equivalent to Institutional Animal Care and Use Committee (IACUC).
With over 1100 Clients and 30+ years of experience in conducting Drug Discovery Services and Development studies, Adgyl Lifesciences is proud of its strong track record of regulatory submissions and robust historical control data and therefore feels confident in developing and thoroughly assessing the safety profile of your molecules. As an extension of your team, our scientists and technicians will help enable and expedite your research goals, ensuring that your preclinical drug development program provides quality data for key decision-making.
Adgyl Lifesciences has successfully submitted 90+ Investigational New Drug (IND) packages to regulatory agencies across the world including USFDA, MHRA and EMA.
